Actively Recruiting

Phase 1
Age: 21Years +
All Genders
ID06413355

Fibroblast Activating Protein (FAP) PET/CT in Adults With Fibrotic Conditions

Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-02-09

45

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the use of Fibroblast Activating Protein (FAP) PET/CT imaging to detect fibrosis caused by various medical conditions where fibrosis is believed to lead to harmful effects and poor outcomes. This phase 1 basket protocol includes patients with fibrosis-inducing diseases such as cancer-associated fibrosis, post-infection, post-radiation, pre or post-transplant, and fibrosis affecting the heart, liver, kidneys, or lungs. The study aims to expand with additional imaging groups as needed to gather clinical data supporting the use of FAP-targeted therapies. Participants will receive an intravenous injection of approximately 6.0 to 8.0 mCi of the radiopharmaceutical [F-18]-FAPI-74, which binds to fibroblast activating protein and allows visualization via PET/CT scan from head to mid-thigh. Some participants may have a second PET/CT scan at a later time to observe changes in fibrosis naturally or in response to therapy. The study includes specific cohorts such as head and neck cancer, post tubercular lung disease, cardiac sarcoidosis, and an exploratory group. During the study, participants will undergo PET/CT imaging sessions to measure the distribution and uptake of [F-18]-FAPI-74 in tissues affected by fibrosis. Imaging results will be compared with clinical pathology and laboratory tests related to fibrosis. The study does not use imaging results to guide treatment decisions, which remain the responsibility of the treating physicians. The primary outcomes focus on PET/CT image analysis over three years. Participation requires informed consent and adherence to imaging procedures.

CONDITIONS

Brief Title

FAPI-74 PET/CT in Adults With Fibrosis

Who Can Participate

Age: 21Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must be 21 years of age or older
  • Diagnosis or suspicion of fibrosis-inducing medical condition
  • For head and neck cancer cohort: diagnosis of oropharyngeal squamous cell carcinoma and surgical candidacy
  • For post tubercular lung disease cohort: microbiologically confirmed drug-sensitive pulmonary tuberculosis and completed TB treatment within 2 years
  • For cardiac sarcoidosis cohort: FDG PET/CT consistent with active cardiac sarcoidosis and clinical suspicion of cardiac involvement
  • Willingness to provide written informed consent and comply with study procedures
Not Eligible

You will not qualify if you...

  • For head and neck cancer cohort: not eligible for tissue resection
  • For post tubercular lung disease cohort: rifampin-resistant TB, alternative pulmonary disease, recent corticosteroid or investigational agent use, or active TB symptoms
  • Women of childbearing potential who are pregnant or breastfeeding
  • Inability to tolerate imaging procedures
  • Any medical condition that may compromise safety or participation
  • Treatment with an agent targeting fibroblast activation protein within 1 month prior to enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Single imaging session with optional additional scan at clinically relevant time points

Participants undergo PET/CT imaging with [F-18]-FAPI-74 to evaluate the presence and distribution of fibrosis in affected tissues and organs.

1 PET/CT imaging visit; an optional second imaging visit may occur depending on clinical needs

Trial Site Locations

Total: 1 location

1

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

Loading map...

Research Team

E

Erin Schubert

M

Mary Hansbury

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here